Doktor axborotnomasi 2024, №2 (114)
Тема статьи
РЕВМАТИК ЮРАК НУҚСОНЛАРИ НЕГИЗИДА РИВОЖЛАНГАН СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИДА ГЕМОДИНАМИК ЎЗГАРИШЛАР ВА ЭМПАГЛИФЛОЗИННИНГ ТАЪСИРИ (28-33)
Авторы
А. Г. Гадаев1, Л. Х. Қаюмов2
Учреждение
1Тошкент тиббиёт академияси, Тошкент, 2Бухоро давлат тиббиёт институти, Бухоро, Ўзбекистон
Аннотация
Мақолада ўтказилган ретроспектив таҳлил юрак ревматик нуқсонлари негизида ривожланган сурункали юрак етишмовчилигида кузатиладиган қатор ўзгаришлар унинг юрак ишемик касаллиги негизида ривожлан ган шаклидан бирмунча фарқ қилиши кўрсатилган. Ундан ташқари юрак нуқсонларида сурункали юрак етишмовчилиги ривожланишига олиб келувчи хавф омиллар кескин континентал Бухоро вилоятида бошқа худудларга нисбатан фарқ қилиши кўрсатилган.
Ключевые слова
ревматик юрак нуқсонлари, сурункали юрак етишмовчилиги, ревматизм, матрал қопқоқчалар етишмовчилиги, аортал стеноз, комбинирланган нуқсонлар, эмпаглифлозин.
Литературы
1. Asrial, A.A.; Reviono, R.; Soetrisno, S.; Setianto, B.Y.; Widyaningsih, V.; Nurwati, I.; Wasita, B.; Pudjiastuti, A. Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis. J. Clin. Med. 2023, 12, 5898. 2. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021 Feb 11;42(6):681-683. doi: 10.1093/eurheartj/ehaa1012. PMID: 33447845; PMCID: PMC7878007. 3. Berliner D, Hänselmann A, Bauersachs J.. The treatment of heart failure with reduced ejection fraction. DtschArz tebl Int 2020;117:376–386. 4. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–1858. 5. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug;22 (8):1342-1356. doi: 10.1002/ejhf.1858. Epub 2020 Jun 1. PMID: 32483830; PMCID: PMC7540043. 6. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart fail ure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032. 7. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, Swedberg K.. Incremental benefit of drug thera pies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018;20:1315–1322. 8. Lin YW, Chen CY, Shih JY, Cheng BC, Chang CP, Lin MT, Ho CH, Chen ZC, Fisch S, Chang WT. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction. J Am Heart Assoc. 2021 Apr 6;10(7):e019274. doi: 10.1161/JAHA.120.019274. Epub 2021 Mar 20. PMID: 33749310; PMCID: PMC8174384. 9. Malik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure. 2023 Nov 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613623. 10. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42: 3599–3726. 11. McMurray J., McDonagh T., Morrison C.E., et al. Trends in hospitalization for the heart failure in Scotland. 1980 1990/ Eur. HeartJ.-1993.-Vol14, №9.-P1158-1162. 12. Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. doi: 10.1038/s41598-019-53540-4. 13. Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021 Oct;18(5):315-328. doi: 10.1007/s11897-021-00529-8. Epub 2021 Sep 15. PMID: 34523061; PMCID: PMC8484236. 14. Peters F, Karthikeyan G, Abrams J, Muhwava L, Zühlke L. Rheumatic heart disease: current status of diagnosis and therapy. Cardiovasc Diagn Ther. 2020 Apr;10(2):305-315. doi: 10.21037/cdt.2019.10.07. PMID: 32420113; PMCID: PMC7225445. 15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the Eu ropean Society of Cardiology (ESC). Eur J Heart Fail 2016;18:891–975. 16. Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023 Mar 13;5(2):82-90. doi: 10.36628/ijhf.2022.0030. PMID: 37180562; PMCID: PMC10172076. 17. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and second ary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393 (10166):31–9. doi: 10.1016/S0140-6736 (18) 32590-X. 18. Татаркина Н. Д., Казанова Л. Р., Шестернин А. Н., Убранцев В. А., Бондарева Ж. В., Татаркин А. А. Гемо динамика при хронической сердечной недостаточности // ТМЖ. 2008. №3 (33).